fda glp-1 compounding enforcement news october 2025 Crackdown FDA Offers Clarification on Compounded

He also noted that the safety profile of GLP-1 receptor agonists in patients with SUDs is unclear especially in populations with high rates of comorbid medical and psychiatric disorders

When you arrive for your infusion, someone will bring you to our comfortable hydration lounge

Huge population, high demand, especially in NYC metro

Butterfield DA, Drake J, Pocernich C, Castegna A

Importantly, GLP-1RAs are able to improve -cell sensitivity to glucose and have the ability to improve the glycaemic profile indirectly by delaying gastric emptying, inhibiting hepatic glucose production and suppressing appetite, thereby promoting weight loss [9,10,11]